|

Blood Biomarkers for Screening of Alzheimer's Disease

RECRUITINGSponsored by Peking University First Hospital
Actively Recruiting
SponsorPeking University First Hospital
Started2024-06-18
Est. completion2026-03-26
Eligibility
Age50 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06477484

Summary

The goal of this observational study is to estimate the screen performance of blood biomarkers of interest (Aβ40 and Aβ42, P-Tau181, P-Tau217, GFAP and NfL) in patients with Alzheimer's disease (AD), mild cognitive impairment due to AD, and cognitively normal individuals. The main questions it aims to answer are: * to identify core blood biomarker suitable for early screening of AD. * to establish a comprehensive model for the early identification of AD.

Eligibility

Age: 50 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age ≥ 50 years;
* AD (meets the 2011 NIA-AA AD diagnostic criteria), or MCI (meets the 2004 Peterson MCI diagnostic criteria), or cognitively normal subjects;
* Signed informed consent form.

Exclusion Criteria:

* The presence of other disorders that can cause cognitive impairment;
* Unable to cooperate with the completion of cognitive assessment;
* Refusal to draw blood.

Conditions2

Alzheimer's DiseaseBlood Biomarkers

Browse More Trials

Alzheimer's Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.